Better Buy: Dynavax Technologies Corp. vs. Geron Corp.

Dynavax Technologies Corp. and Geron Corp. have pending catalysts that could cause their shares to double from current levels. Here's a Foolish look at which company offers the better risk-to-reward profile.

Jul 4, 2014 at 7:50AM

Beaten-down biotechs have an odd way of making heroic comebacks. But to catch lightning in a bottle by bottom feeding in the biotech arena, you need to understand why the company's share price cratered in the first place -- and what needs to unfold for the stock to come roaring back,

Dynavax Technologies (NASDAQ:DVAX) and Geron (NASDAQ:GERN) are two small-cap biotechs that have fallen on hard times due to regulatory issues surrounding their flagship clinical candidates. And although both companies have rebounded since their dramatic declines, they are still trading well below their former highs. With this in mind, let's consider which company has the better chance of regaining its former market share going forward. 

GERN Chart

GERN data by YCharts

Dynavax's hepatitis B vaccine could spark a comeback
Dynavax's share price cratered last year after the Food and Drug Administration requested additional clinical trial data to more thoroughly explore the safety profile of Heplisav, the company's experimental hepatitis B vaccine. Although a late-stage trial showed that the vaccine is more effective in a broader array of patient populations than GlaxoSmithKline's (NYSE:GSK) Engerix-B, the study wasn't sufficiently powered to detect rare but serious side effects. 

Dynavax has since initiated a new late-stage trial that will both provide further insight into Heplisav's safety profile and investigate the vaccine's efficacy in type 2 diabetics. This trial is expected to conclude in late 2015 -- putting it on track for new regulatory filings in both the U.S. and EU by early 2016. With a commercial opportunity that is projected to hover around $700 million per year in peak sales, Dynavax looks undervalued at its current market cap of $415 million.

Geron's troubled blood cancer drug might ignite a rally
After a tumultuous history of clinical trials with a handful of potentially revolutionary new medicines, Geron's new management has decided to focus squarely on developing imetelstat as a treatment for a diversity of blood-based cancers. So far, imetelstat has shown impressive efficacy results as a treatment for myelofibrosis, with some patients even going into complete remission.

What's noteworthy about this result is that the only approved drug for myelofibrosis, Incyte's (NASDAQ:INCY) Jakafi, does not result in disease remission, meaning that imetelstat could be a breakthrough therapy for this difficult to treat disease. 

Even so, imetelstat has showed some worrisome signs of increasing the risk of liver toxicity in its ongoing clinical trials -- leading the FDA to place a clinical hold on the drug last March and causing shares to plummet by over 50% in a single day.

Since then, the agency has lifted the partial hold for the myelofibrosis trial, but it remains in place for other indications such as essential thrombocythemia, polycythemia vera, and multiple myeloma. The company also cannot initiate any new clinical trials for the drug until this issue is resolved. 

Going forward, Geron is required to perform additional preclinical studies to clarify imetelstat's safety profile before the full hold can be released. While some investors are arguing that the agency will release the hold sooner rather than later, it's important to understand that these new studies won't be completed for at least a few months, if not longer.

Foolish wrap-up
Clinical trials are inherently risks, given that something goes wrong more often than not. So, there is a real chance that neither one of these companies will reach and/or surpass their former glory.

That being said, I am cautiously optimistic that Dynavax will ultimately see Heplisav through to an approval. My belief is based on the fact that no major red flags popped up in the clinical trial data thus far that would suggest it will turn out to be unsafe -- or at least its benefits won't outweigh the risks in certain difficult to treat subpopulations.

By contrast, imetelstat's safety profile has proven to be a real concern, leading to the clinical hold in the first place. Perhaps the ongoing preclinical studies will warrant lifting imetelstat's hold for other indications, but Heplisav looks like the safer bet, in my opinion. And given that the potential upside for each stock looks roughly similar, I think Dynavax is a better speculative buy in this case.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell owns shares of Dynavax Technologies. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information